TG Therapeutics (TGTX) Stock Forecast, Price Target & Predictions
TGTX Stock Forecast
TG Therapeutics stock forecast is as follows: an average price target of $23.75 (represents a -28.83% downside from TGTX’s last price of $33.37) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
TGTX Price Target
The average price target for TG Therapeutics (TGTX) is $23.75 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $27.50 to $20.00. This represents a potential -28.83% downside from TGTX's last price of $33.37.
TGTX Analyst Ratings
According to 7 Wall Street analysts, TG Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TGTX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
TG Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 05, 2024 | Edward White | H.C. Wainwright | $27.50 | $12.93 | 112.68% | -17.59% |
| Aug 06, 2024 | Corinne Jenkins | Goldman Sachs | $20.00 | $20.58 | -2.82% | -40.07% |
| May 03, 2024 | Edward White | H.C. Wainwright | $24.50 | $8.21 | 198.42% | -26.58% |
| Feb 07, 2023 | Cantor Fitzgerald | $24.00 | $18.48 | 29.87% | -28.08% | |
| Dec 30, 2022 | Evercore ISI | $16.00 | $11.83 | 35.25% | -52.05% | |
| Dec 29, 2022 | Edward White | H.C. Wainwright | $12.00 | $4.23 | 183.69% | -64.04% |
| Apr 19, 2022 | Goldman Sachs | $5.00 | $7.26 | -31.13% | -85.02% | |
| Apr 18, 2022 | Mayank Mamtani | Telsey Advisory | $11.50 | $3.46 | 232.37% | -65.54% |
The latest TG Therapeutics stock forecast, released on Nov 05, 2024 by Edward White from H.C. Wainwright, set a price target of $27.50, which represents a 112.68% increase from the stock price at the time of the forecast ($12.93), and a -17.59% decrease from TGTX last price ($33.37).
TG Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $27.50 | $24.00 |
| Last Closing Price | $33.37 | $33.37 | $33.37 |
| Upside/Downside | -100.00% | -17.59% | -28.08% |
In the current month, the average price target of TG Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to TG Therapeutics's last price of $33.37. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 29, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 29, 2024 | Cowen & Co. | Buy | Initialise | |
| Oct 24, 2024 | B. Riley | Buy | Buy | Hold |
| Sep 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 06, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| May 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 02, 2023 | Goldman Sachs | Sell | Neutral | Upgrade |
| Dec 30, 2022 | Jefferies | Buy | Buy | Hold |
| Dec 30, 2022 | Goldman Sachs | Sell | Sell | Hold |
| Dec 30, 2022 | Evercore ISI | Outperform | Outperform | Hold |
| Dec 30, 2022 | B. Riley Securities | Buy | Buy | Hold |
| Dec 29, 2022 | B. Riley | Buy | Buy | Hold |
| Dec 29, 2022 | Morgan Stanley | Underperform | Underperform | Hold |
| Dec 29, 2022 | H.C. Wainwright | Buy | Buy | Hold |
TG Therapeutics's last stock rating was published by H.C. Wainwright on Oct 29, 2024. The company gave TGTX a "Buy" rating, the same as its previous rate.
TG Therapeutics Financial Forecast
TG Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $43.97M | $165.81M | $16.07M | $7.80M | $80.00K | $94.00K | $594.00K | $2.02M | $2.32M | $2.03M | $1.54M | $793.00K | $38.00K | $38.00K | $38.00K | $38.00K | $38.00K | $38.00K | $38.00K | $38.00K |
| Avg Forecast | $167.40M | $144.37M | $129.66M | $113.48M | $99.36M | $81.70M | $65.92M | $54.60M | $40.06M | $23.91M | $17.39M | $3.38M | $1.60M | $1.46M | $175.43K | $2.08M | $2.24M | $2.97M | $3.60M | $820.29K | $19.00K | $19.00K | $22.80K | $22.80K | $22.80K | $34.50K | $19.00K | $25.33K |
| High Forecast | $173.85M | $149.93M | $134.66M | $118.59M | $104.81M | $81.94M | $65.92M | $54.60M | $40.18M | $23.91M | $18.06M | $3.51M | $1.68M | $1.46M | $175.43K | $2.08M | $2.24M | $2.97M | $3.60M | $820.29K | $19.00K | $19.00K | $22.80K | $22.80K | $22.80K | $34.50K | $19.00K | $25.33K |
| Low Forecast | $158.51M | $136.70M | $122.78M | $106.24M | $94.48M | $81.47M | $65.92M | $54.60M | $39.88M | $23.91M | $16.47M | $3.20M | $1.54M | $1.46M | $175.43K | $2.08M | $2.24M | $2.97M | $3.60M | $820.29K | $19.00K | $19.00K | $22.80K | $22.80K | $22.80K | $34.50K | $19.00K | $25.33K |
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | 1.10% | 6.93% | 0.92% | 2.31% | 0.05% | 0.06% | 3.39% | 0.97% | 1.04% | 0.68% | 0.43% | 0.97% | 2.00% | 2.00% | 1.67% | 1.67% | 1.67% | 1.10% | 2.00% | 1.50% |
TG Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $54.60M, with a low forecast of $54.60M, and a high forecast of $54.60M. TGTX's average Quarter revenue forecast represents a 24.18% increase compared to the company's last Quarter revenue of $43.97M (Dec 23).
TG Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | $-12.48M | $114.78M | $-43.98M | $-36.39M | $-50.13M | $-34.04M | $-37.49M | $-66.22M | $-92.18M | $-84.52M | $-76.81M | $-88.67M | $-86.87M | $-85.51M | $-50.62M | $-49.88M | $-37.65M | $-60.37M | $-35.11M | $-35.13M |
| Avg Forecast | $-130.18M | $-112.27M | $-100.83M | $-88.25M | $-77.27M | $-63.54M | $-51.27M | $-42.46M | $-31.16M | $-18.60M | $-13.53M | $-2.63M | $-1.25M | $-1.14M | $-137.18K | $-49.39M | $-1.75M | $-2.32M | $-2.82M | $-57.73M | $-14.86K | $-66.09M | $-17.83K | $-17.83K | $-17.83K | $-26.98K | $-14.86K | $-19.81K |
| High Forecast | $-123.26M | $-106.31M | $-95.48M | $-82.62M | $-73.48M | $-63.36M | $-51.27M | $-42.46M | $-31.02M | $-18.60M | $-12.81M | $-2.49M | $-1.20M | $-1.14M | $-137.18K | $-39.51M | $-1.75M | $-2.32M | $-2.82M | $-46.18M | $-14.86K | $-52.87M | $-17.83K | $-17.83K | $-17.83K | $-26.98K | $-14.86K | $-19.81K |
| Low Forecast | $-135.20M | $-116.60M | $-104.72M | $-92.22M | $-81.51M | $-63.72M | $-51.27M | $-42.46M | $-31.25M | $-18.60M | $-14.05M | $-2.73M | $-1.31M | $-1.14M | $-137.18K | $-59.26M | $-1.75M | $-2.32M | $-2.82M | $-69.27M | $-14.86K | $-79.30M | $-17.83K | $-17.83K | $-17.83K | $-26.98K | $-14.86K | $-19.81K |
| Surprise % | - | - | - | - | - | - | - | - | 0.40% | -6.17% | 3.25% | 13.85% | 40.19% | 29.90% | 273.31% | 1.34% | 52.63% | 36.42% | 27.25% | 1.54% | 5847.34% | 1.29% | 2839.31% | 2797.97% | 2111.45% | 2237.64% | 2363.40% | 1773.59% |
5 analysts predict TGTX's average Quarter EBITDA for Dec 23 to be $-31.16M, with a high of $-31.02M and a low of $-31.25M. This is -127.14% lower than TG Therapeutics's previous annual EBITDA (Sep 23) of $114.78M.
TG Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | $-14.42M | $113.93M | $-47.61M | $-38.63M | $-53.92M | $-36.67M | $-42.08M | $-71.15M | $-93.73M | $-86.15M | $-79.50M | $-92.05M | $-89.65M | $-88.60M | $-54.92M | $-51.99M | $-41.18M | $-63.00M | $-36.88M | $-35.62M |
| Avg Forecast | $62.22M | $67.68M | $37.62M | $26.43M | $25.11M | $4.82M | $-7.33M | $-9.64M | $-16.11M | $9.19M | $-40.42M | $-58.26M | $-43.57M | $-56.60M | $-76.52M | $-51.45M | $-101.23M | $-90.87M | $-82.90M | $-59.00M | $-95.43M | $-67.36M | $-53.89M | $-57.07M | $-73.02M | $-53.81M | $-64.83M | $-69.35M |
| High Forecast | $65.34M | $71.08M | $39.51M | $27.75M | $40.81M | $5.06M | $-6.82M | $-8.98M | $-13.43M | $9.65M | $-37.63M | $-54.24M | $-41.26M | $-56.60M | $-76.52M | $-41.16M | $-101.23M | $-90.87M | $-82.90M | $-47.20M | $-95.43M | $-53.89M | $-53.89M | $-57.07M | $-73.02M | $-53.81M | $-64.83M | $-69.35M |
| Low Forecast | $57.93M | $63.01M | $35.02M | $23.49M | $12.56M | $4.49M | $-7.70M | $-10.13M | $-17.46M | $8.55M | $-42.44M | $-61.18M | $-46.42M | $-56.60M | $-76.52M | $-61.74M | $-101.23M | $-90.87M | $-82.90M | $-70.80M | $-95.43M | $-80.83M | $-53.89M | $-57.07M | $-73.02M | $-53.81M | $-64.83M | $-69.35M |
| Surprise % | - | - | - | - | - | - | - | - | 0.89% | 12.40% | 1.18% | 0.66% | 1.24% | 0.65% | 0.55% | 1.38% | 0.93% | 0.95% | 0.96% | 1.56% | 0.94% | 1.32% | 1.02% | 0.91% | 0.56% | 1.17% | 0.57% | 0.51% |
TG Therapeutics's average Quarter net income forecast for Dec 23 is $-16.11M, with a range of $-17.46M to $-13.43M. TGTX's average Quarter net income forecast represents a -114.14% decrease compared to the company's last Quarter net income of $113.93M (Sep 23).
TG Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | $31.15M | $26.50M | $36.38M | $29.65M | $28.26M | $17.50M | $14.97M | $22.50M | $56.46M | $34.90M | $34.02M | $26.76M | $43.86M | $35.30M | $14.43M | $14.26M | $7.06M | $2.91M | $2.72M | $2.34M |
| Avg Forecast | $33.20B | $28.63B | $25.72B | $22.51B | $19.71B | $16.20B | $13.07B | $10.83B | $7.95B | $4.74B | $3.45B | $670.15M | $318.16M | $288.71M | $34.79M | $412.66M | $444.22M | $588.55M | $714.97M | $162.69M | $3.77M | $3.77M | $4.52M | $4.52M | $4.52M | $6.84M | $3.77M | $5.02M |
| High Forecast | $34.48B | $29.74B | $26.71B | $23.52B | $20.79B | $16.25B | $13.07B | $10.83B | $7.97B | $4.74B | $3.58B | $696.00M | $334.15M | $288.71M | $34.79M | $412.66M | $444.22M | $588.55M | $714.97M | $162.69M | $3.77M | $3.77M | $4.52M | $4.52M | $4.52M | $6.84M | $3.77M | $5.02M |
| Low Forecast | $31.44B | $27.11B | $24.35B | $21.07B | $18.74B | $16.16B | $13.07B | $10.83B | $7.91B | $4.74B | $3.27B | $634.56M | $305.18M | $288.71M | $34.79M | $412.66M | $444.22M | $588.55M | $714.97M | $162.69M | $3.77M | $3.77M | $4.52M | $4.52M | $4.52M | $6.84M | $3.77M | $5.02M |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 0.01% | 0.01% | 0.04% | 0.09% | 0.06% | 0.43% | 0.05% | 0.13% | 0.06% | 0.05% | 0.16% | 11.64% | 9.37% | 3.19% | 3.15% | 1.56% | 0.43% | 0.72% | 0.47% |
TG Therapeutics's average Quarter SG&A projection for Mar 24 is $10.83B, based on 4 Wall Street analysts, with a range of $10.83B to $10.83B. The forecast indicates a 34662.49% rise compared to TGTX last annual SG&A of $31.15M (Dec 23).
TG Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | $-0.10 | $0.80 | $-0.34 | $-0.28 | $-0.39 | $-0.27 | $-0.31 | $-0.53 | $-0.71 | $-0.65 | $-0.60 | $-0.70 | $-0.72 | $-0.74 | $-0.49 | $-0.49 | $-0.43 | $-0.70 | $-0.42 | $-0.44 |
| Avg Forecast | $0.39 | $0.42 | $0.23 | $0.16 | $0.16 | $0.03 | $-0.05 | $-0.06 | $-0.10 | $0.06 | $-0.25 | $-0.36 | $-0.27 | $-0.35 | $-0.48 | $-0.61 | $-0.64 | $-0.57 | $-0.52 | $-0.56 | $-0.60 | $-0.41 | $-0.34 | $-0.36 | $-0.46 | $-0.34 | $-0.41 | $-0.43 |
| High Forecast | $0.41 | $0.44 | $0.25 | $0.17 | $0.25 | $0.03 | $-0.04 | $-0.06 | $-0.08 | $0.06 | $-0.23 | $-0.34 | $-0.26 | $-0.35 | $-0.48 | $-0.61 | $-0.64 | $-0.57 | $-0.52 | $-0.56 | $-0.60 | $-0.41 | $-0.34 | $-0.36 | $-0.46 | $-0.34 | $-0.41 | $-0.43 |
| Low Forecast | $0.36 | $0.39 | $0.22 | $0.15 | $0.08 | $0.03 | $-0.05 | $-0.06 | $-0.11 | $0.05 | $-0.26 | $-0.38 | $-0.29 | $-0.35 | $-0.48 | $-0.61 | $-0.64 | $-0.57 | $-0.52 | $-0.56 | $-0.60 | $-0.41 | $-0.34 | $-0.36 | $-0.46 | $-0.34 | $-0.41 | $-0.43 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 14.00% | 1.35% | 0.77% | 1.44% | 0.76% | 0.65% | 0.87% | 1.12% | 1.14% | 1.15% | 1.26% | 1.20% | 1.79% | 1.45% | 1.37% | 0.94% | 2.07% | 1.03% | 1.01% |
According to 5 Wall Street analysts, TG Therapeutics's projected average Quarter EPS for Dec 23 is $-0.10, with a low estimate of $-0.11 and a high estimate of $-0.08. This represents a -112.53% decrease compared to TGTX previous annual EPS of $0.80 (Sep 23).
TG Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.18 | $70.00 | 38788.89% | Buy |
| PDSB | PDS Bio | $1.52 | $9.00 | 492.11% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| TERN | Terns Pharmaceuticals | $4.18 | $18.67 | 346.65% | Buy |
| BTAI | BioXcel Therapeutics | $0.33 | $1.00 | 203.03% | Buy |
| VKTX | Viking Therapeutics | $33.43 | $98.00 | 193.15% | Buy |
| EXEL | Exelixis | $32.96 | $33.17 | 0.64% | Buy |
| MDGL | Madrigal Pharmaceuticals | $326.33 | $315.75 | -3.24% | Buy |
| AKRO | Akero Therapeutics | $54.00 | $50.00 | -7.41% | Buy |
| TGTX | TG Therapeutics | $33.37 | $23.75 | -28.83% | Buy |